HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lars Farde Selected Research

5-HT1B Serotonin Receptor

1/2016Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676.
7/20155-HT1B receptor imaging and cognition: a positron emission tomography study in control subjects and Parkinson's disease patients.
8/2014Reduced 5-HT(1B) receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder.
7/2008[11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lars Farde Research Topics

Disease

27Schizophrenia (Dementia Praecox)
01/2022 - 01/2002
13Alzheimer Disease (Alzheimer's Disease)
01/2022 - 06/2006
12Parkinson Disease (Parkinson's Disease)
01/2020 - 10/2004
12Mental Disorders (Mental Disorder)
01/2018 - 03/2002
6Psychotic Disorders (Schizoaffective Disorder)
01/2022 - 01/2018
6Major Depressive Disorder (Major Depressive Disorders)
01/2019 - 11/2011
6Amyloid Plaque
12/2015 - 06/2006
5Neurodegenerative Diseases (Neurodegenerative Disease)
01/2022 - 04/2008
4Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
09/2009 - 02/2005
3Neoplasms (Cancer)
12/2021 - 01/2020
2Brain Neoplasms (Brain Tumor)
01/2021 - 01/2020
2Cognitive Dysfunction
01/2016 - 09/2014
2Neuroinflammatory Diseases
12/2015 - 09/2015
2Anxiety Disorders (Anxiety Disorder)
02/2014 - 11/2013
2Juvenile Myoclonic Epilepsy
02/2012 - 06/2005
2Cerebrovascular Disorders (Cerebrovascular Occlusion)
11/2002 - 08/2002
1Synucleinopathies
01/2022
1Ataxia Telangiectasia (Louis Bar Syndrome)
12/2021
1Glioblastoma (Glioblastoma Multiforme)
12/2021
1Autistic Disorder (Autism)
01/2021
1Neoplasm Metastasis (Metastasis)
01/2021
1Nervous System Diseases (Neurological Disorders)
01/2021
1Epilepsy (Aura)
01/2020
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2020
1Type 2 Diabetes Mellitus (MODY)
12/2018
1Autism Spectrum Disorder
10/2018
1Antisocial Personality Disorder (Antisocial Personality)
01/2018
1Necrosis
04/2017
1Weight Loss (Weight Reduction)
02/2016
1Obesity
02/2016
1Gliosis
12/2015
1Brain Diseases (Brain Disorder)
06/2015
1Mood Disorders (Mood Disorder)
05/2015
1Mania (Manias)
11/2013

Drug/Important Bio-Agent (IBA)

18Pharmaceutical PreparationsIBA
01/2020 - 01/2002
14Dopamine (Intropin)FDA LinkGeneric
01/2022 - 05/2002
12Serotonin (5 Hydroxytryptamine)IBA
01/2022 - 03/2002
9Antipsychotic Agents (Antipsychotics)IBA
01/2022 - 05/2002
7Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA
01/2019 - 09/2000
7Amyloid (Amyloid Fibrils)IBA
11/2017 - 11/2009
6Dopamine D2 Receptors (Dopamine D2 Receptor)IBA
09/2021 - 01/2002
6Biomarkers (Surrogate Marker)IBA
01/2020 - 06/2006
5FLB 457IBA
09/2021 - 01/2002
4Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
01/2021 - 01/2003
4Proteins (Proteins, Gene)FDA Link
01/2019 - 09/2015
4Dopamine Receptors (Dopamine Receptor)IBA
01/2018 - 05/2002
45-HT1B Serotonin ReceptorIBA
01/2016 - 07/2008
4Amyloid beta-PeptidesIBA
09/2015 - 03/2009
42- (6- (methylamino)pyridin- 3- yl)- 1,3- benzothiazol- 6- olIBA
09/2015 - 03/2009
3RacloprideIBA
12/2006 - 02/2005
2G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
01/2022 - 11/2017
25-HT1A Serotonin ReceptorIBA
01/2022 - 06/2005
2osimertinibIBA
01/2021 - 01/2020
2Monoamine Oxidase (MAO)IBA
12/2020 - 01/2020
2LigandsIBA
01/2020 - 12/2015
2Metabotropic Glutamate 5 ReceptorIBA
01/2020 - 01/2018
2SCH 23390IBA
01/2019 - 05/2002
2Biological ProductsIBA
01/2018 - 03/2010
2Neurotransmitter Agents (Neurotransmitter)IBA
11/2015 - 12/2014
2AZD3241IBA
09/2015 - 06/2015
2Peroxidase (Myeloperoxidase)IBA
09/2015 - 06/2015
2Quetiapine Fumarate (Seroquel)FDA Link
11/2013 - 11/2011
2Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
08/2013 - 09/2012
2N- (3- iodoprop- 2- enyl)- 2- beta- carbomethoxy- 3- (4- methylphenyl)nortropaneIBA
02/2012 - 02/2005
2Clozapine (Clozaril)FDA LinkGeneric
11/2011 - 03/2003
2vinpocetineIBA
11/2002 - 08/2002
1Protein Kinases (Protein Kinase)IBA
12/2021
1AZD1390IBA
12/2021
1AfatinibIBA
01/2021
1Fluorine-18IBA
12/2020
1Carbon-11IBA
12/2020
1Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA
01/2020
1ErbB Receptors (EGF Receptor)IBA
01/2020
1Dopamine D1 Receptors (Dopamine D1 Receptor)IBA
01/2020
1Tyrosine Kinase InhibitorsIBA
01/2020
1fenobamIBA
01/2020
1AZD9272IBA
01/2020
1Antidepressive Agents (Antidepressants)IBA
01/2019
1VortioxetineIBA
01/2019
1Insulin (Novolin)FDA Link
12/2018
1Aminobutyrates (Aminobutyric Acid)IBA
10/2018
1Glutamic Acid (Glutamate)FDA Link
01/2018
1ApolipoproteinsIBA
11/2017
1Apolipoproteins E (ApoE)IBA
11/2017
1Glucose (Dextrose)FDA LinkGeneric
11/2017
1Tumor Biomarkers (Tumor Markers)IBA
04/2017
1N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamideIBA
02/2016
1RimonabantIBA
02/2016
1CB1 Cannabinoid Receptor (CB1 Receptor)IBA
02/2016
1N,N- dimethyl- 7- (4- (2- (pyridin- 2- yl)ethyl)piperazin- 1- yl)benzofuran- 2- carboxamideIBA
01/2016
1benzofuranIBA
01/2016
1Peptides (Polypeptides)IBA
12/2015
1Reactive Oxygen Species (Oxygen Radicals)IBA
09/2015
1Norepinephrine (Noradrenaline)FDA LinkGeneric
12/2014
1AutoreceptorsIBA
08/2014
1AminesIBA
06/2014

Therapy/Procedure

2Therapeutics
08/2014 - 04/2013
1Drug Therapy (Chemotherapy)
01/2022
1Radiotherapy
12/2021
1Aftercare (After-Treatment)
09/2015